Compare GSK plc (GSK) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.94. The key difference: GSK plc pays a 3.49% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none, and GSK plc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| GSK | SJNK | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $25.63 |
52-Week Low | $36.20 | $24.75 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SJNK trades at $24.945, up 0.14% for the day, with a bearish technical signal from moving averages but neutral oscillators. The ETF maintains a consistent dividend payout schedule, with recent distributions of $0.14 and $0.15 per share. Financial ratios are not applicable as this is a bond ETF tracking high-yield corporate debt.
Outlook remains cautious amid bearish technicals and negative analyst sentiment citing exhausted tailwinds. Risks include interest rate sensitivity and credit spread volatility. Institutional interest persists, but current conditions favor monitoring for stability before entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
